foto

Prof. dr. D.L.P. Baeten

Main activities
Research
Focus of research

Immunopathology of chronic inflammatory arthritis

Key publications
  • Dougados M, Baeten D, Spondyloarthritis. LANCET 2011;377 (9783):2127-2137 [PubMed]
  • Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W, Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. LANCET 2013;382 (9906):1705-1713 [PubMed]
  • Baeten DLP , Kuchroo VK, How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases. NAT MED 2013;19 (7):824-825 [PubMed]
  • Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB [Contributors: van den Bosch F, Nzeusseu A, de Vlam K, Geusens P, Oparanov B, Rashkov R, Batalov A, Goranov I, Kazmin I, McCarthy T, Inman R, Rahman P, Schaeverbeke T, N'Guyen M, Bertin P, Frediani B, Adami S, Foti R, Triolo G, Fusaro E, Franceschini F, Zazueta B, Maradiaga M, Avila H, Garza M, Baeten D, Bijlsma H, Berrocal A, Garro B, Gamboa R, Castaneda O, Becerra F, Stanislav M, Salnikova T, Maslyanskiy A, Ershova O, Izmozherova N, Lesniak O, Tseng JC, Wei CC, Ozdogan H, Kisacik B, Onen F, Tahir H, Ostor A, Barkham N, Kay L, Braun J, Dahmen G, Rubbert-Roth A, Wassenberg S, Oelzner P, Nuesslein H, Moericke R, Rech J, Sieper J, Deodhar A, Kivitz A, Aelion J, Kohen M, Knibbe W, LaSalle S, Zang S, Cohen S, Brooks M, Graninger W, Jorg R, Zamani O, Bessette L, Cohen M, Beaulieu A, Pavelka K, Galatikova D, Dokoupilova E, Leirisalo-Repo M, Paimela L, Järvinen P, Sokka-Isler T, Rouhe E, keskussairaala S, Pellerito R, Bijlsma J, Trofimov V, Vezikova N, Zotkin E, Mosesova N, Lee LN, Cheung P, Balsa A, Blanco R, Blanco FJ, Gonzalez C, Bannert B, Daniela B, Dudler J, Ciurea A, Marzo-Ortega H, Gaffney K, Mackay K, Codding C, Dorman W, Legerton C 3rd, Khan M, Lee E, Caldron P, Wolfe JF, Swarup A, Singhal A, Tony HP]] , Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. NEW ENGL J MED 2015;373 (26):2534-2548 [PubMed]
  • Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Caňete JD, Baeten D, Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. ARTHRITIS RHEUM-US 2012;64 (1):99-109 [PubMed]
All Publications
Curriculum Vitae

NAME: Baeten Dominique, MD, PhD
BIRTH: 12/12/1970

Academic carreer
• Physician (MD), University of Ghent, Belgium, 1995, Cum Maxima Laude
• Doctor in the Medical Sciences (PhD), University of Ghent, Belgium, 2001, Cum Maxima Laude
• Legal Degree of Specialist in Rheumatology, Belgium, 2002
• Assistant Professor (docent), Ghent University, Belgium, 2003
• Associate Professor (hoofddocent) Academic Medical Center/University of Amsterdam, The Netherlands, 2006.
• Professor of Rheumatology, University of Amsterdam, The Netherlands, 2012

Key personal grants and awards
• Fund for Scientific Research-Flanders Research Fellowship (1996)
• Fund for Scientific Research-Flanders Senior Clinical Investigator (2002)
• European League Against Rheumatism Young Investigator Award (2002)
• Academic Medical Center Fellowship (2006)
• NWO Vernieuwingsimpuls VIDI Grant (2007)
• NWO Vernieuwingsimpuls VICI Grant (2014)
• European Research Council (ERC) Consolidator grant (2015)

Key scientific publications
• Baeten D, Bettelli E, et al. J Clin Invest 2006;116:2393-402.
• Dougados M, Baeten D. Lancet 2011;377:2127-37.
• Baeten D, Baraliakos X, et al. Lancet 2013;382:1705-13.
• Baeten D, Kuchroo V. Nat Med 2013;19:824-5.
• Sieper J, Braun J, Dougados M, Baeten D. Nat Rev Dis Prim 2015 (accepted)
• Baeten D, Sieper J, et al. N Engl J Med 2015 (accepted).

Key international experience
• Research Fellowship at INSERM U437, Nantes, France, Oct 2003-Oct 2004.
• Research Fellowship at Harvard Medical School and Brigham and Women’s Hospital, Boston, USA, Oct 2004-Oct 2005.
• Principal Investigator of the Ghent University Hospital in the FP6 program ‘Autocure’
• Co-principal Investigator of the AMC/UvA in the IMI EU program ‘BTCure’
• Chair of the EU COST Action: European Network for Translational Immunology Research and Education (ENTIRE), 2010-2014.

Key managerial experience
• Executive Professional Training, Audencia Business School, Nantes, France, 2004.
• Director of the FOCIS Center of Excellence, Academic Medical Center/University of Amsterdam, The Netherlands, 2006-present.
• Chair of the Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, The Netherlands, 2011- 2013.
• Chair of the EU COST Action: European Network for Translational Immunology Research and Education (ENTIRE), 2010-2014.
 

Research programmes

Immunopathology of chronic inflammatory arthritis

1) B cell autoimmunity: we study the cellular and molecular mechanisms operating in human autoreactive B cells, using mainly ACPA-positive B cells as model. In collaboration with Prof Hergen Spits, we cloned a large series of normal and autoreactive memory B cells from rheumatoid arthritis patients and healthy controls. We study key molecular switches in these cells, including mechanisms related to co-stimulation, germinal center formation, cytokine production, and B-T cell interactions. In collaboration with Dr Niek de Vries, we study the clonal expansion and repertoires of these autoreactive cells.

2) Cellular and molecular pathways of chronic tissue inflammation: using synovial inflammation in human spondyloarthritis as model, we study how key cytokine axis (in particular: TNF and IL-23/IL-17) operate in chronic tissue inflammation.  

3) Animal models of spondyloarthritis: rheumatic diseases are not only characterized by chronic inflammation but also by pronounced structural damage to musculoskeletal organs. Spondyloarthritis is characterized by pathological new bone formation, which is very difficult to study in humans as this is a very slow process and access to tissue samples is difficult. Therefore, we set up animal models of SpA which allow us to mechanistaically study the interaction between inflammation and new bone formation and to preclinically test novel therapeutic strategies.

4) Novel therapies in spondyloarthritis: in this clinical part of our research program, we conduct phase II and IIIa clinical trials (both investigator-initiated and pharma-driven) with novel compounds in spondyloarthritis. Biological samples obtained in these trials are used for translational lab reserach (see 2). Moreover, we study biomarkers that can help us to select and stratify patient populations of appropriate treatment strategies.

5) Fc receptors as key determinants of myeloid cell-driven inflammation: this program is driven by a junior independent researcher, Jeroen den Dunnen (VENI and AMC Fellowship) and studies how different Fc receptors interact with TLRs to determine the myeloid immune response in infection and inflammation.


Theme: Infection and Immunity

Faculty
Prof. dr. D.L.P. Baeten

Postdocs
L.M. van Duivenvoorde PhD
Dr. J. den Dunnen PhD
C.M. Fehres PhD
Dr. M.G.H. van de Sande MD
N.G. Yeremenko PhD

PhD Students
S. Chen
J.W. Hoepel MSc
H.M.Y. de Jong
M.H. Kaaij
P. Kabala MSc
M.J. Levels
Drs. A. Musters MD
M. Newling

Others
I. Blijdorp
J. Burgstede
I. Fluri
T. Heijda
T.E. Latuhihin
M. Leeuw MSc
D. Pots
A. van Tillo
M.N. van Tok
Drs. N.O. van Uden

Current research funding
  • AMC
  • AMC (Vrijgesteld)
  • CTC Maastricht
  • Europese Unie
  • Merck & Co., Inc
  • Novartis Pharma AG
  • NWO